PT - JOURNAL ARTICLE AU - Pedro Gutiérrez-Castrellón AU - Tania Gandara-Martí AU - Ana Teresa Abreu AU - Cesar D. Nieto-Rufino AU - Eduardo López-Orduña AU - Irma Jiménez-Escobar AU - Carlos Jiménez-Gutiérrez AU - Gabriel López-Velazquez AU - Jordi Espadaler-Mazo TI - Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial AID - 10.1101/2021.05.20.21256954 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.20.21256954 4099 - http://medrxiv.org/content/early/2021/05/24/2021.05.20.21256954.short 4100 - http://medrxiv.org/content/early/2021/05/24/2021.05.20.21256954.full AB - Background Probiotics have been proposed as adjuvants for Coronavirus Disease 2019 (Covid19) but randomized controlled trials (RCT) are lacking.Methods Single-center, quadruple-blinded RCT. Symptomatic Covid 19 outpatients (aged 18 to 60 years) with positive SARS-CoV2 nucleic acids test were randomized to active (n=150; ≥2×109 colony-forming units (CFU) of probiotic strains Lactiplantibacillus plantarum KABP022, KABP023 and KAPB033, plus strain Pediococcus acidilactici KABP021) or placebo (n=150), take orally once daily for 30 days. Oral acetaminophen was allowed and controlled as co-intervention. Primary endpoint included: i) proportion of patients in complete remission (both symptoms and nucleic acids test) or progressing to moderate or severe disease with hospitalization; ii) death rate and duration on Intensive Care Unit (ICU). Safety was assessed in all patients. This study is registered at ClinicalTrials.gov (NCT04517422).Findings 300 subjects were randomized (median age 37.0 years [range 18 to 60], 161 [53.7%] women, 126 [42.0%] having known metabolic risk factors), and 293 completed the study (97.7%). Remission was achieved by 78 of 147 (53.1%) in the active group compared to 41 of 146 (28.1%) in placebo (P<0.0001; ARR=25.0% [95%CI 14.1-35.9%]), still significant after multiplicity correction for the primary endpoint. No hospitalizations or deaths occurred during the study, precluding the assessment of efficacy on these endpoints. No serious adverse events occurred during the study. Replication studies with this probiotic formula are warranted.Competing Interest StatementJEM is a full-time scientist with no stock options at Kaneka AB-Biotics SA (Barcelona, Spain), the company which provided the probiotic used in this study. ATAA reports receiving speaker fees from Kaneka AB-Biotics SA, BioGaia (Stockholm, Sweden) and Mayoly-Spindler (Chatou, France). PGC reports receiving speaker and consulting fees from BioGaia (Stockholm, Sweden). All other authors report their institution was supported by Kaneka AB-BIOTICS SA for the submitted work but have no additional competing interests. All authors have completed the ICMJE uniform disclosure form. All the authors and Kaneka AB-BIOTICS SA vouch for the accuracy and completeness of the data.Clinical TrialNCT04517422Funding StatementThis study was funded by AB-Biotics S.A (Barcelona, Spain), a member of the KANEKA Group (Japan).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Research Ethics Committee of Hospital General Dr. Manuel Gea Conzalez of Mexico City (approval number 12-120-2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan. To make a request, please contact the corresponding author (espadaler{at}ab-biotics.com). Decision to make IPD publicly available was taken after initial trial registration.